$VRTX
AI AnalysisGenerated on May 11, 2026
AI Score
Buy$VRTX
Vertex Pharmaceuticals
$VRTXNASDAQHealthcareLarge-Cap
Vertex discovers and develops medicines for cystic fibrosis and other serious diseases.
Market Cap
$105.0B
Revenue (TTM)
$10.3B
+12.0%
Net Income (TTM)
$3.8B
+15.0%
EPS (TTM)
$14.80
P/E Ratio
28.0
Dividend Yield
0.0%
52-Week Range
$350-$500
Beta
0.42
Dimension Scores
Fundamental
80Technical
72Sentiment
76Risk / Reward
78Momentum
74Financial Health
Profitability
85strong
Growth
77strong
Liquidity
86strong
Solvency
82strong
Efficiency
78strong
Valuation, technical analysis, investment thesis, risk assessment and more for $VRTX
Free · No credit card required
Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.